Patents by Inventor Sue Cramp

Sue Cramp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS
    Publication number: 20240190854
    Abstract: Compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the substituents are defined in the specification. The compounds are hyperpolarisation activated cyclic-nucleotide modulated ion channel 2 (HCN2) inhibitors. Also disclosed are pharmaceutical compositions comprising the compounds, and the use of the compounds for the treatment or prevention of medical conditions mediated by HCN2, including neuropathic pain.
    Type: Application
    Filed: March 2, 2022
    Publication date: June 13, 2024
    Applicant: King's College London
    Inventors: Peter A. McNaughton, Karen Williams, Sue Cramp, Alan Naylor
  • PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS
    Publication number: 20240174639
    Abstract: Compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the substituents are defined in the specification. The compounds are hyperpolarisation activated cyclic-nucleotide modulated ion channel 2 (HCN2) inhibitors. Also disclosed are pharmaceutical compositions comprising the compounds, and the use of the compounds for the treatment or prevention of medical conditions mediated by HCN2, including neuropathic pain.
    Type: Application
    Filed: March 2, 2022
    Publication date: May 30, 2024
    Applicant: King's College London
    Inventors: Peter A. McNaughton, Karen Williams, Sue Cramp, Alan Naylor
  • PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS
    Publication number: 20240174663
    Abstract: Compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein the substituents are defined in the specification. The compounds are hyperpolarisation activated cyclic-nucleotide modulated ion channel 2 (HCN2) inhibitors. Also disclosed are pharmaceutical compositions comprising the compounds, and the use of the compounds for the treatment or prevention of medical conditions mediated by HCN2, including neuropathic pain.
    Type: Application
    Filed: March 2, 2022
    Publication date: May 30, 2024
    Applicant: King's College London
    Inventors: Peter A. McNaughton, Karen Williams, Sue Cramp, Alan Naylor
  • Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase
    Patent number: 11407767
    Abstract: This invention related to compounds that are inhibitors of the CDK12 kinase. The compounds are useful in the treatment of disorders mediated by the CDK12 kinase including myotonic dystrophy type 1 (DM1) and other disorders caused by the generation of RNA repeat expansion transcripts. In particular, the invention relates to compounds of the formula (I), or a pharmaceutically acceptable salts or N-oxides thereof, wherein R1a, R2, R3, R4a, R4b and R4c are as defined herein.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: August 9, 2022
    Inventors: David Brook, Chris Hayes, Nicholas Bennett, Matthew Palframan, Sue Cramp, Richard Bull, Michael Bodnarchuk
  • HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE
    Publication number: 20200247824
    Abstract: This invention related to compounds that are inhibitors of the CDK12 kinase. The compounds are useful in the treatment of disorders mediated by the CDK12 kinase including myotonic dystrophy type 1 (DM1) and other disorders caused by the generation of RNA repeat expansion transcripts. In particular, the invention relates to compounds of the formula (I), or a pharmaceutically acceptable salts or N-oxides thereof, wherein R1a, R2, R3, R4a, R4b and R4c are as defined herein.
    Type: Application
    Filed: September 21, 2018
    Publication date: August 6, 2020
    Applicant: The University of Nottingham
    Inventors: David Brook, Chris Hayes, Nicholas Bennett, Matthew Palframan, Sue Cramp, Richard Bull, Michael Bodnarchuk
  • Pyrimidine Compounds as Histamine Modulators
    Publication number: 20080269239
    Abstract: The present invention relates to novel pyrimidine compounds, for the modulation of the histamine H4 receptor and the treatment or prevention of conditions mediated by the histamine H4 receptor. The invention also relates to the preparation of such compounds.
    Type: Application
    Filed: November 11, 2005
    Publication date: October 30, 2008
    Applicant: Argenta Discovery Ltd.
    Inventors: Neil Harris, Christopher Higgs, Stephen Wren, Hazel Dyke, Steven Price, Sue Cramp
  • Pyrimidine Compounds for the Treatment of Inflammatory Disorders
    Publication number: 20080261946
    Abstract: The present invention relates to novel pyrimidine compounds, for the modulation of the histamine H4 receptor and the treatment or prevention of conditions mediated by the histamine H4 receptor. The invention also relates to the preparation of such compounds.
    Type: Application
    Filed: September 20, 2006
    Publication date: October 23, 2008
    Applicant: CELLZOME (UK) LTD.
    Inventors: Hazel Dyke, Steven Price, Sue Cramp